Oxford Genetics is a specialist synthetic biology company based in Oxford, United Kingdom, and our goal is to accelerate the discovery, development and production of proteins, antibodies, viruses and bio-therapeutics (biologics, gene/cell therapies) through the application of synthetic biology. We are focused on providing DNA, protein, virus and cell line solutions for mammalian expression and bio-production. From DNA design/synthesis, through antibody development, and using vectors to produce proteins/antibodies/viruses on the backend, Oxford Genetics delivers. Our team pride themselves on understanding the biological purpose of our customer’s projects, and work hand-in-hand to design, construct and validate the systems needed, providing a complete synthetic biology solution from design to delivery.
OxStem is a drug discovery company, spun-out from the University of Oxford in 2016, with the unique vision of developing small molecule therapeutics that augment repair mechanisms that already exist within the body. OxStem is developing drug candidates that can awaken endogenous cells to repair tissues affected by disease or injury to treat diseases such as Dementia, Heart Failure, Macular Degeneration (the leading cause of blindness in the developed world) and Oncology.